A novel maize variety designated PH1W03 and seed, plants and plant parts thereof. Methods for producing a maize plant that comprise crossing maize variety PH1W03 with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH1W03 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. Hybrid maize seed, plant or plant part produced by crossing the variety PH1W03 or a locus conversion of PH1W03 with another maize variety.

A novel maize variety designated PH1MBR and seed, plants and plant parts thereof. Methods for producing a maize plant that comprise crossing maize variety PH1MBR with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH1MBR through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. Hybrid maize seed, plant or plant part produced by crossing the variety PH1MBR or a locus conversion of PH1MBR with another maize variety.

A novel maize variety designated PH1K8P and seed, plants and plant parts thereof. Methods for producing a maize plant that comprise crossing maize variety PH1K8P with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH1K8P through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. Hybrid maize seed, plant or plant part produced by crossing the variety PH1K8P or a locus conversion of PH1K8P with another maize variety.

A novel maize variety designated PH1KHH and seed, plants and plant parts thereof. Methods for producing a maize plant that comprise crossing maize variety PH1KHH with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH1KHH through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. Hybrid maize seed, plant or plant part produced by crossing the variety PH1KHH or a locus conversion of PH1KHH with another maize variety.

A novel maize variety designated PH18WR and seed, plants and plant parts thereof. Methods for producing a maize plant that comprise crossing maize variety PH18WR with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH18WR through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. Hybrid maize seed, plant or plant part produced by crossing the variety PH18WR or a locus conversion of PH18WR with another maize variety.

A novel maize variety designated PH1M0H and seed, plants and plant parts thereof. Methods for producing a maize plant that comprise crossing maize variety PH1M0H with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH1M0H through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. Hybrid maize seed, plant or plant part produced by crossing the variety PH1M0H or a locus conversion of PH1M0H with another maize variety.

A novel maize variety designated PH1KAP and seed, plants and plant parts thereof. Methods for producing a maize plant that comprise crossing maize variety PH1KAP with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH1KAP through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. Hybrid maize seed, plant or plant part produced by crossing the variety PH1KAP or a locus conversion of PH1KAP with another maize variety.

A novel maize variety designated PH18PF and seed, plants and plant parts thereof. Methods for producing a maize plant that comprise crossing maize variety PH18PF with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH18PF through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. Hybrid maize seed, plant or plant part produced by crossing the variety PH18PF or a locus conversion of PH18PF with another maize variety.

A novel maize variety designated PH1TDJ and seed, plants and plant parts thereof. Methods for producing a maize plant that comprise crossing maize variety PH1TDJ with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into PH1TDJ through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. Hybrid maize seed, plant or plant part produced by crossing the variety PH1TDJ or a locus conversion of PH1TDJ with another maize variety.

A novel maize variety designated X130721 and seed, plants and plant parts thereof, produced by crossing Pioneer Hi-Bred International, Inc. proprietary inbred maize varieties. Methods for producing a maize plant that comprises crossing hybrid maize variety X130721 with another maize plant. Methods for producing a maize plant containing in its genetic material one or more traits introgressed into X130721 through backcross conversion and/or transformation, and to the maize seed, plant and plant part produced thereby. This invention relates to the maize variety X130721, the seed, the plant produced from the seed, and variants, mutants, and minor modifications of maize variety X130721. This invention further relates to methods for producing maize varieties derived from maize variety X130721.

Provided herein are mitochondrial-nuclear exchanged cells and animals comprising mitochondrial DNA (mtDNA) from one subject and nuclear DNA (nDNA) from a different subject. Methods for producing a mitochondrial-nuclear exchanged animal and animals made by the methods are provided. Also provided are methods of screening for agents useful for treating a disease or disorder using mitochondrial-nuclear exchanged animals or cells, tissues or organs thereof.

The present invention relates to methodology and constructs for modifying plant architecture and enhancing plant biomass and/or sucrose yield.

The invention relates to the soybean variety designated A1035446. Provided by the invention are the seeds, plants and derivatives of the soybean variety A1035446. Also provided by the invention are tissue cultures of the soybean variety A1035446 and the plants regenerated therefrom. Still further provided by the invention are methods for producing soybean plants by crossing the soybean variety A1035446 with itself or another soybean variety and plants produced by such methods.

A barley cultivar, designated BG-161, is disclosed. The invention relates to seeds, plants, and hybrids of barley cultivar BG-161, and methods for producing a barley plant produced by crossing plants from barley cultivar BG-161 with themselves or plants from another barley variety. The invention also relates to methods for producing a barley plant containing in its genetic material one or more transgenes and to the transgenic barley plants and plant parts produced by those methods. The invention also relates to barley varieties derived from barley cultivar BG-161, to methods for producing other barley varieties, lines or plant parts derived from barley cultivar BG-161, and to the barley plants, varieties, and their parts derived from the use of those methods. The invention further relates to hybrid barley seeds and plants produced by crossing barley cultivar BG-161 with another barley cultivar.

According to the invention, there is provided seed and plants of the hybrid corn variety designated CH715413. The invention thus relates to the plants, seeds and tissue cultures of the variety CH715413, and to methods for producing a corn plant produced by crossing a corn plant of variety CH715413 with itself or with another corn plant, such as a plant of another variety. The invention further relates to genetic complements of plants of variety CH715413.

The invention provides specific transgenic soybean plants, plant material and seeds, characterized in that these products harbor a stack of specific transformation events at specific locations in the soybean genome (elite event EE-GM3 and elite event EE-GM2, or elite event EE-GM3 and elite event EE-GM1). The invention also provides for methods of producing soybean plants and seeds having elite event EE-GM3 and elite event EE-GM2, or elite event EE-GM3 and elite event EE-GM1.

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

A mixing device for mixing a first and second material together to create an output mixture. The device includes a first chamber containing the first material coupled to a mixing chamber defined between a rotor and a stator. The rotor is disposed inside the stator and rotates therein about an axis of rotation. The first chamber houses an internal pump configured to pump the first material from the first chamber into the mixing chamber. The pump may be configured to impart a circumferential velocity into the first material before it enters the mixing chamber. At least one of the rotor and stator have a plurality of through-holes through which the second material is provided to the mixing chamber. Optionally, a second chamber is coupled to the mixing chamber. The second chamber may house an internal pump configured to pump the output material from the mixing chamber into the second chamber.

A device for depositing a mixture of powders to form an object with composition gradients, including: a plurality of tanks respectively configured to contain different powders; a powder mixer placed under the tanks and including a rotatably mounted mixing member; a plurality of powder dispensing mechanisms respectively cooperating with the tanks, and each configured to regulate mass flow rate of the powder escaping from a respective of the tanks towards the mixer; a powder mixture collector placed under the mixer; and a powder mixture dispenser placed under the collector.

A cartridge for squeezing-out a cartridge content, like a cement, or a medical cement, having a cylindrical hollow space bordered by a cartridge wall, a feed plunger arranged in the hollow space to be mobile along the cylinder axis of the hollow space and abutting the cartridge wall, and at least one snap-in means for locking the feed plunger in place at the cartridge wall, to a locking device arranged on the feed plunger and comprises at least a snap-in means which is accessible from outside when the feed plunger is locked. The invention also provides a cartridge system with a cartridge for squeezing out content and a method for dispensing such cartridge content, preferably a cement, through the use of a cartridge of said type.

A method of mixing together liquids or liquid/solid combinations, and mixing apparatus/universal combine utilizing a vertical spinning container or vessel having a rib, or a cross rib in its bottom wall. The container is spun about a vertical axis with no wobbling component to the motion. Meshed elements are used for high shear mixing. Start/stop routines, and variable acceleration/speed values are used, to facilitate complete mixing. Use of ‘impeller’ blade stirrers is completely eliminated.

A gravimetric blender has a frame; a resin material storage hopper supported by the frame, including a hopper cover; a weigh bin located below the hopper for receiving resin material from the hopper downwardly discharging the bin contents after the contents have been weighed; a load cell, connecting the frame and the weigh bin, for sensing weight of the weigh bin; a mixer connected to the frame, below the hopper, for mixing received contents of the weigh bin; and a guide connected to the frame, for movement of the hopper cover therealong.

Mixer for biphasic compounds, including a chamber for containing a solid phase and a cartridge containing a phial of a liquid phase, said chamber and said cartridge being able to communicate through respective channels, wherein said cartridge includes an external casing made in a deformable material and said phial is of the breakable type.

The present invention relates to an apparatus for mixing and controlling the temperature of laboratory vessel contents with an accommodating device in detachable connection with an exchangeable block for accommodating and controlling the temperature of laboratory vessels and with a drive by which the accommodating device can be set in a mixing motion, and with a temperature control device with a heat source or sink in heat-conducting connection with the exchangeable block at least through in each case at least one adjoining contact face firstly on the accommodating device and secondly on the exchangeable block, which is characterized in that the detachable connection is maintained by a spring element which, by virtue of its spring force, horizontally clamps together a first undercut between the accommodating device and the exchangeable block in at least one first direction.

An apparatus for containing and mixing a load of liquids and solids is disclosed. The apparatus includes an elongated tank, which includes a lower portion and an upper portion. The apparatus further includes an elongated rotatable shaft within the tank. At least one blade is connected to the shaft and is configured to mix the liquids and solids when the shaft is rotated. The apparatus also includes a shaft support configured for maintaining the shaft in a rotatable manner within the tank. The shaft support is selectively moveable in a manner permitting the shaft to move in an upward direction from the lower portion toward the upper portion, and in a downward direction from the upper portion toward the lower portion. An is contained with the tank for moving the shaft support in the upward direction and in the downward direction.

A container (10, 30, 50) is provided for single- or multi-component molding materials. The container has a container body (12, 32, 52) having a constant outer contour in a longitudinal extent of the container (10, 30, 50), a piston (17, 37) movable in the longitudinal direction, and a cover (11, 31) having an outlet opening (13, 33, 53). A volume for a molding material is defined between the piston (17, 37) and the cover (11, 31), the volume being variable in the direction of the longitudinal extent of the container (10, 30, 50). The container distinguishes itself in that the container body (12, 32, 52) is rotatable relative to the outlet opening (13, 33, 53), and the piston (17, 37) thereby pushes out the content of the container (10, 30, 50).

A mixing and kneading machine (1) for continual compounding comprises a screw shaft (3) rotating in a casing (2) and simultaneously moving axially translationally. To sustainably enhance the efficiency of the machine as regards its material thruput per unit of time the screw shaft (3) comprises at least four groups of radial screw vanes (4a, 4b, 4c, 4d) evenly distributed circumferentially, each group consisting of a plurality of screw vanes in axial sequence. The outer diameter (Da) of the screw shaft ranges from 400 to 800 millimeters. The rotary speed of the screw shaft (3) ranges from 30 to 80 rpm. A mixing and kneading machine (1) engineered as such is particularly suitable for compounding an anodic mass in the production of electrodes—anodes—for the aluminum industry.

The present invention discloses a high intensity ultrasonic treatment method and apparatus that is used in conjunction with an existing commercial dough or batter mixer to enhance the rheological, aeration and textural properties of the dough or batter. This change in properties is a result of the phenomenon of acoustic cavitation induced in the dough or batter by treatment with high intensity ultrasonic waves. The present invention discloses a mixing bowl (20) of an existing mixer system that is preloaded with dough or batter, the bowl (20) is located at the center of an ultrasonic bath tank (101) filled with a working fluid. The effect of ultra-sonic waves with power levels above 1 kW can be observed over the entire or partial mixing period of the dough or batter. The ultra-sonic waves of the present invention are generated by a plurality of ultrasonic wave generators (104A, 104B) and piezoelectric transducers (1) mounted on a stainless steel tank (101). The electrical energy received in each transducer (1) will be converted into appropriate mechanical expansion and contractions in the piezoelectric ceramics of the transducer (1) thus leading to pressure waves being transmitted to the dough or batter to be mixed. The generation and transmission of high intensity ultrasonic waves to the dough or batter affects its rheological, aeration and textural properties.

An improved dual-shaft preconditioner (10) of simplified design is provided giving increased moisturization and partial cooking of food or feed ingredients. The preconditioner (10) includes an elongated, tapered housing (12) presenting a pair of side-by-side, communicating housing sections (58, 60), with a corresponding pair of converging shafts (20, 22) within the sections (58, 60) and having a series of elongated, outwardly extending mixing elements (24, 26) secured to the shafts (20, 22). The preconditioner (10) is designed for use in a system including a downstream processing device, such as an extruder (146).

An agitator, particularly for abrasive media includes a support disk to which agitator blades are connected substantially perpendicular to the support disk. The blades are arranged substantially in a radial direction. The support disk also includes a hub that receives an agitator shaft which is preferably motor-driven. The trailing faces of the blades of the agitator and/or the area of the blade connections to the support disk are designed to largely prevent vortex shedding. This is accomplished by implementing a specific geometry for the agitator blades, the support disk, and the connection of the blades to the support disk.

A compact portable blender system features a base unit. A base unit top surface features a recess having an “L” shaped locking slot and a motor with a drive gear. A base unit bottom surface features a removable power supply. The base unit features a power charger, a removable cord, a cord storage cavity, a power switch, and a power indicator. The system features a blending container. A blending blade unit is located on a container bottom. A blade drive gear located on a blending blade unit bottom and a blending blade is located on a blending blade unit top. The blending blade unit features a locking tab located on a blending blade unit side wall. The system features a container lid having an aperture. The container lid features a cover located over the aperture on a container lid top.

The present invention relates to the field of organic chemistry and in particular to organic free radicals used as polarizing agents in the technique of Dynamic Nuclear Polarization (DNP), which involves transferring the polarization of electron spins to the nuclei of a compound whose Nuclear Magnetic Resonance (NMR) is being observed. It concerns Dinitroxide-type Biradical polarizing agents characterized by a rigid linkage between the aminoxyl groups of said nitroxide units. This particular structure enables, at low temperatures and high fields, optimal transfer of polarization and optimal enhancement of NMR/MAS signals of the polarized nuclei of the compound studied.

This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

The invention provides a process of preparing an intermediate useful in the synthesis of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and a process of preparing a crystalline freebase of the ester.

A process for preparing the compound of the following formula (E): wherein Bn represents a benzyl group, and tBu represents a tert-butyl group, the process including: (a) subjecting the following compound (B) to trifluoroacetylation, wherein tBu represents a tert-butyl group to produce the following compound (C): wherein tBu represents a tert-butyl group, and TFA represents a trifluoroacetyl group; (b) reacting the compound (C) with benzyloxyamine in the presence of a hydroxyl group activating agent to produce the following compound (D): wherein Bn represents a benzyl group, tBu represents a tert-butyl group, and TFA represents a trifluoroacetyl group; and (c) subjecting the compound (D) to detrifluoroacetylation.

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

A description is given of N-(1,2,5-oxadiazol-3-yl)pyridinecarboxamides of the general formula (I) as herbicides. R in this formula (I) stands for radicals such as hydrogen, organic radicals, and other radicals such as halogen. W stands for a substituted pyridyl radical.

The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.

The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.

A method of manufacturing an anhydrous copper complex of formula C12H10CICuN2O4 and methods of treating neuromuscular and other diseases, including but not limited to fibromyalgia, multiple sclerosis, muscular dystrophy, rheumatoid arthritis, pain, fatigue, sleeplessness, loss of fine motor control, speech loss, inflexibility, Alzheimer's, dementia, amyotrophic lateral sclerosis, depression, lyme disease, lyme disease co-infection, gastroparesis (GP), myopathy, chronic inflammation and/or incontinence. The anhydrous copper complex preferably is administered in a pharmaceutical and/or dietary supplement composition of the invention.

This disclosure is directed to fused tetracyclic pyrido[4,3-b>]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

The present disclosure relates to Oxime-Substituted Quinoxaline-Type Piperidine Compounds, such as those of Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R20, R21, Q, Y1, Z, A, B, and a are as defined herein; compositions comprising an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Oxime-Substituted Quinoxaline-Type Piperidine Compound.

The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.

The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).

The present invention provides compounds having the general structural formula (I), and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.

The invention is directed to novel substituted benzylamino quinolines, compounds comprising substituted benzylamino quinolines, methods of making substituted benzylamino quinolines, the use of substituted benzylamino quinolines for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism, and the use of substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors.

The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

Cyanine dye compounds having a substituted methine moiety that are nucleic acid stains, particularly for fluorescent staining of RNA, including compounds having the formula where R1 is a C1-C6 alkyl, sulfoalkyl, carboxyalkyl or C1-C6 alkoxy; each R2 is independently selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, fused benzo, trifluoromethyl, amino, sulfo, carboxy and halogen, that is optionally further substituted; at least one of R3, R4, and R5 is an alkyl, aryl, heteroaryl, cyclic, or heterocyclic moiety that is optionally substituted by alkyl, amino, aminoalkyl, carboxy, nitro, or halogen; and the remaining R3, R4 or R5 are hydrogen; X is S, O, or Se; and D is a substituted or unsubstituted pyridinium, quinolinium or benzazolium moiety.

Many GTPases such as Ras, Ral and Rho require post-translational farnestylation or geranylgeranylation for mediating malignant transformation. Dual farnesyltransferase (FT) (FTI) and geranylgeranyltransferase-I (GGT-1) inhibitors (GGTI) were developed as anticancer agents from based on an ethylenediamine scaffold. On the basis of a 4-fold substituted ethylenediamine scaffold, the inhibitors are structurally simple and readily derivatized, facilitating extensive structure-activity relationship studies. The most potent inhibitor is compound exhibited an in vitro hFTase IC50 value of 25 nM and a whole cell H-Ras processing IC50 value of 90 nM. Several of the inhibitors proved highly selective for hFTase over the related prenyltransferase enzyme geranylgeranyltransferase-I (GGTase-I). A crystal structure of an inhibitor cocrystallized with farnesyl pyrophosphate in the active site of rat FTase illustrates that the para-benzonitrile moiety is stabilized by a π-π stacking interaction with the Y361β residue, suggesting an importance of this component of the inhibitors.

There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.